Amphastar Pharmaceuticals, Inc. Lease, Cost
Amphastar Pharmaceuticals, Inc. (AMPH) reported Lease, Cost of $3.61 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-05-07
- Amphastar Pharmaceuticals, Inc. lease, cost for the quarter ending 2026-03-31 was $3.61M, a 41.84% increase year-over-year.
- Amphastar Pharmaceuticals, Inc. lease, cost for the quarter ending 2025-03-31 was $2.55M.
- Amphastar Pharmaceuticals, Inc. lease, cost for the quarter ending 2019-12-31 was $1.37M.
- Amphastar Pharmaceuticals, Inc. lease, cost for the quarter ending 2019-09-30 was $1.33M.
- Amphastar Pharmaceuticals, Inc. lease, cost for fiscal 2025 was $10.17M, a 50.64% increase from fiscal 2024.
- Amphastar Pharmaceuticals, Inc. lease, cost for fiscal 2024 was $6.75M, a 15.72% increase from fiscal 2023.
- Amphastar Pharmaceuticals, Inc. lease, cost for fiscal 2023 was $5.83M, a 10.64% increase from fiscal 2022.
- Amphastar Pharmaceuticals, Inc. lease, cost for fiscal 2022 was $5.27M, a 0.30% increase from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-03-31 | $3.61M 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $10.17M 10-K · filed 2026-02-26 | |||
| 2025-03-31 | $2.55M 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | $6.75M 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $5.83M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $5.27M 10-K · filed 2025-03-03 | |||
| 2021-12-31 | $5.26M 10-K · filed 2024-02-29 | |||
| 2020-12-31 | $5.50M 10-K · filed 2023-03-01 | |||
| 2019-12-31 | $1.37M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $2.70M derived: sum of 2 quarters · filed 2022-03-11 | $3.88M derived: sum of 3 quarters · filed 2022-03-11 | $4.99M 10-K · filed 2022-03-11 |
| 2019-09-30 | $1.33M 10-Q · filed 2019-11-08 | $2.51M derived: sum of 2 quarters · filed 2019-11-08 | $3.62M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $1.18M 10-Q · filed 2019-08-09 | $2.29M 10-Q · filed 2019-08-09 | ||
| 2019-03-31 | $1.11M 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |